Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

9800	Companies
196495	Keywords
127493	Articles
104459	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 02/17/2025 at 09:32, 11 months 15 days ago

Formycon AG fait le point sur ses projets biosimilaires et ses ajustements stratégiques

Stratégie Commerciale Approbation De La FDA Biosimilaires Ajustements Financiers Réductions De Prix
BRIEF

published on 02/17/2025 at 09:32, 11 months 15 days ago

Formycon AG Updates on Biosimilar Projects and Strategic Adjustments

FDA Approval Biosimilars Financial Adjustments Commercial Strategy Price Discounts
PRESS RELEASE

published on 02/17/2025 at 09:27, 11 months 15 days ago

Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
Formycon AG provides updates on various biosimilar projects, including terminating phase III trial for FYB206. Conference call on Feb 17, 2025, to discuss recent developments

FDA Conference Call Formycon AG FYB206 Biosimilar Projects
BRIEF

published on 02/17/2025 at 08:10, 11 months 15 days ago

Formycon Updates on Phase III Trial and Valuation Adjustments

Formycon AG FDA Feedback Phase III Trial Commercialization Strategy Biosimilar Valuation
BRIEF

published on 02/17/2025 at 08:10, 11 months 15 days ago

Formycon fait le point sur l'essai de phase III et les ajustements de valorisation

Formycon AG Stratégie De Commercialisation Essai De Phase III Commentaires De La FDA Évaluation Des Biosimilaires
PRESS RELEASE

published on 02/17/2025 at 08:05, 11 months 15 days ago

EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
Formycon terminates Phase III trial for FYB206 after FDA feedback, anticipates valuation adjustments for FYB202 & FYB201 due to price discounts

FDA Feedback Valuation Adjustments Formycon FYB206 Price Discounts
BRIEF

published on 02/05/2025 at 06:35, 11 months 27 days ago

Lotus Pharmaceutical Partners with Formycon to Commercialize Eylea® Biosimilar in Asia-Pacific

Lotus Pharmaceutical Eylea® Biosimilar Asia-Pacific Commercialization FDA And EU Approval Retinal Disease Treatment
BRIEF

published on 02/05/2025 at 06:35, 11 months 27 days ago

Lotus Pharmaceutical s'associe à Formycon pour commercialiser le biosimilaire Eylea® en Asie-Pacifique

Lotus Pharmaceutique Biosimilaire Eylea® Commercialisation En Asie-Pacifique Approbation De La FDA Et De L'UE Traitement Des Maladies De La Rétine
PRESS RELEASE

published on 02/05/2025 at 06:30, 11 months 27 days ago

Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region
Formycon AG announces strategic partnership with Lotus Pharmaceutical for commercialization of Eylea biosimilar FYB203/AHZANTIVE in Asia-Pacific region

Formycon AG Asia-Pacific Eylea Biosimilar FYB203/AHZANTIVE Lotus Pharmaceutical
BRIEF

published on 01/20/2025 at 06:35, 1 year ago

Formycon Secures EU Approval for Biosimilar FYB203

Formycon AG EU Approval Teva Pharmaceuticals Aflibercept Biosimilar FYB203

Accesswire

Published on 02/04/2026 at 02:15, 10 hours 4 minutes ago

Future Fuels Announces $2 Million LIFE Flow-Through Offering
Published on 02/04/2026 at 00:00, 12 hours 19 minutes ago

Sintana Energy Inc. Announces VMM-37 Resolution
Published on 02/03/2026 at 23:30, 12 hours 49 minutes ago

FutureGen Industries Retains Market-Making Services
Published on 02/03/2026 at 23:12, 13 hours 7 minutes ago

Appointment of Credit Advisor for Stage 1 Operations
Published on 02/03/2026 at 22:30, 13 hours 49 minutes ago

Green Bridge Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$4 Million

View all ACCESSWIRE

EQS Group

Published on 02/04/2026 at 11:55, 24 minutes ago

Form 8.3 - Lupus alpha Asset Management AG: Kitwave Group plc
Published on 02/04/2026 at 11:43, 35 minutes ago

Schweizer Electronic AG significantly strengthens its ESG profile with a CDP climate rating of ‘B’
Published on 02/04/2026 at 11:07, 1 hour 12 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 02/04/2026 at 11:05, 1 hour 14 minutes ago

AUSTRIACARD Successfully Achieves mada Card Chip Profile Certification
Published on 02/04/2026 at 11:03, 1 hour 16 minutes ago

Amundi Physical Metals plc: Final Terms

Les Echos

Published on 02/04/2026 at 11:59, 19 minutes ago

LNA Santé : Répartition de capital et des droits de vote attachés aux actions au 31/01/2026
Published on 02/04/2026 at 11:51, 27 minutes ago

Janvier 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Published on 02/03/2026 at 19:18, 17 hours ago

Paulic Meunerie - Chiffre d'Affaires 2025
Published on 02/03/2026 at 18:00, 18 hours 19 minutes ago

Mint dépasse ses ambitions annoncées pour 2025 grâce à des succès commerciaux majeurs dans le BtoB
Published on 02/03/2026 at 17:45, 18 hours 34 minutes ago

Informations relatives au nombre total de droits de vote et d’actions

View all LES ECHOS COMFI WIRE